Article
Medicine, General & Internal
Ismaeel Yunusa, Joshua J. Gagne, Kazuki Yoshida, Katsiaryna Bykov
Summary: In this cohort study, patients treated with paroxetine or fluoxetine were found to have a slightly increased risk of opioid overdose when initiating oxycodone. This study highlights the importance of considering the potential drug-drug interactions when prescribing opioids.
Article
Pharmacology & Pharmacy
Taiji Miyake, Tatsuki Mochizuki, Toshito Nakagawa, Mikiko Nakamura, Chie Emoto, Natsuko Komiyama, Manabu Hirabayashi, Satoshi Tsuruta, Tomofumi Shimojo, Kimio Terao, Tatsuhiko Tachibana
Summary: The study demonstrates how CYP3A-mediated drug-drug interactions can be predicted using Hu-PXB mice. In vitro fm was overestimated, and Hu-PXB mice showed better correlation in CLtotal change with humans compared to SCID mice.
BRITISH JOURNAL OF PHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Jun Wang, Xiao Cui, Chen Cheng, Yi Wang, Wei Sun, Cheng-Ke Huang, Rui-Jie Chen, Zhe Wang
Summary: The study found that ketoconazole and voriconazole significantly increased the exposure of sunitinib, decreased the exposure of N-desethyl sunitinib, and inhibited the metabolism of sunitinib in rats. However, itraconazole showed only a weak effect on pharmacokinetics and metabolism. Coadministration of sunitinib with ketoconazole and voriconazole should be avoided or closely monitored.
CHEMICO-BIOLOGICAL INTERACTIONS
(2021)
Article
Medical Laboratory Technology
Ibrahim Choucair, Cristina Figueroa Villalba, Michael A. Vera, Gina Cassella-Mclane, Thomas J. S. Durant, Joe M. El-Khoury
Summary: This study evaluated the frequency and concentration of hydrocodone and its metabolite, hydromorphone, in the urine of patients taking oxycodone to determine if the ratio of hydrocodone or hydromorphone to oxycodone could differentiate between exclusive oxycodone use and concomitant use of other opiates. The results showed that hydrocodone and/or hydromorphone can be detected in patients taking only oxycodone, and their presence can be identified as an impurity if the calculated ratio to oxycodone is below 1%.
CLINICAL BIOCHEMISTRY
(2023)
Review
Pharmacology & Pharmacy
Malavika Deodhar, Jacques Turgeon, Veronique Michaud
Summary: Oxycodone, a widely used opioid for chronic pain management, exerts its analgesic effects through agonistic actions on the mu-opioid receptor. Variability in oxycodone efficacy is linked to polymorphisms in the gene coding for the mu-opioid receptor (OPRM1). The CYP2D6 enzyme plays a key role in the conversion of oxycodone to its active metabolite oxymorphone, with implications for analgesic efficacy.
Article
Health Care Sciences & Services
Florine M. Wiss, Celine K. Stauble, Henriette E. Meyer zu Schwabedissen, Samuel S. Allemann, Markus L. Lampert
Summary: Patients with chronic pain can have different responses to analgesic medications. Genetic variants can affect the response to opiates, non-opioid analgesics, and antidepressants for neuropathic pain treatment. This case report highlights the importance of an in-depth medication review, including pharmacogenetic analysis, to find better treatment options for patients with complex pain syndromes.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Dominique A. Garrison, Yan Jin, Zahra Talebi, Shuiying Hu, Alex Sparreboom, Sharyn D. Baker, Eric D. Eisenmann
Summary: This study found that pretreatment with itraconazole significantly increased the systemic exposure to gilteritinib in mice, similar to the observed clinical drug-drug interaction. Furthermore, it revealed that gilteritinib is a substrate of OATP1B-type transporters and that the ability of itraconazole to inhibit OATP1B-type transport is dependent on its metabolism by CYP3A isoforms.
Article
Pharmacology & Pharmacy
Feng Zhang, Tiantian Zhang, Jiahao Gong, Qinqin Fang, Shenglan Qi, Mengting Li, Yan Han, Wei Liu, Guangbo Ge
Summary: This study demonstrates that the Chinese herb Styrax can efficiently inhibit hCYP3A4 enzyme and modulate the pharmacokinetic behavior of CYP3A-substrate drugs. It provides valuable insights for clinical pharmacologists to assess the potential herb-drug interactions triggered by Styrax or Styrax-related herbal products.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Eric D. Eisenmann, Dominique A. Garrison, Zahra Talebi, Yan Jin, Josie A. Silvaroli, Jin-Gyu Kim, Alex Sparreboom, Michael R. Savona, Alice S. Mims, Sharyn D. Baker
Summary: The study found that antifungal drugs can increase Venetoclax exposure by inhibiting both CYP3A-mediated metabolism and OATP1B-mediated transport, especially antifungal drugs such as ketoconazole and micafungin. These findings have important implications for the co-administration of drugs that inhibit both CYP3A-mediated metabolism and OATP1B-mediated transport.
Article
Pharmacology & Pharmacy
Miao Xu, Liang Zheng, Jin Zeng, Wenwen Xu, Xuehua Jiang, Ling Wang
Summary: This study established PBPK models to investigate the influence of CYP2D6 gene polymorphism on tramadol pharmacokinetics and predict potential drug-drug interactions. The models accurately described tramadol and M1 exposure in different CYP2D6 phenotypes, suggesting dose adjustments and predicting inhibitor-substrate interactions when tramadol was co-administered with CYP2D6 inhibitors.
Article
Pharmacology & Pharmacy
Hongjuan Guo, Yueyue Li, Ji Qiu
Summary: Liensinine inhibits the activity of human liver cytochrome P450 (CYP) enzymes in a time-dependent manner, with significant inhibition on CYP3A. It suggests the potential drug-drug interaction between liensinine and drugs metabolized by CYP3A, 2D6, or 2C19.
LATIN AMERICAN JOURNAL OF PHARMACY
(2021)
Article
Chemistry, Multidisciplinary
Lu Liu, Wei Li, Le Yang, Zi-tao Guo, Hao Xue, Ning-jie Xie, Xiao-yan Chen
Summary: Almonertinib, a novel EGFR tyrosine kinase inhibitor, is metabolized by CYP3A, with the major active metabolite being N-desmethyl almonertinib (HAS-719). Co-administration with itraconazole increased almonertinib levels but reduced HAS-719 levels, while rifampicin decreased levels of both almonertinib and HAS-719. Further metabolism of HAS-719 may contribute to its altered pharmacokinetics when combined with rifampicin.
ACTA PHARMACOLOGICA SINICA
(2022)
Article
Pharmacology & Pharmacy
Diane Ramsden, Elke S. Perloff, Andrea Whitcher-Johnstone, Thuy Ho, Reena Patel, Kirk D. Kozminski, Cody L. Fullenwider, J. George Zhang
Summary: Coupling time-dependent inactivation parameters derived from pooled human hepatocytes and human liver microsomes (HLM) with a mechanistic static model provides an easy and quantitatively accurate means to determine clinical drug-drug interaction risk from in vitro data. Optimization is needed to evaluate time-dependent inhibition (TDI) for weak and moderate inhibitors using HLM. Recommendations are made with respect to input parameters for in vitro to in vivo extrapolation (IVIVE) of TDI with non-CYP3A enzymes using available data from HLM and human hepatocytes.
DRUG METABOLISM AND DISPOSITION
(2022)
Article
Genetics & Heredity
Gerd Jakobsson, Ronja Larsson, Lucia Pelle, Robert Kronstrand, Henrik Green
Summary: This study investigates the impact of CYP2D6 phenotype on oxycodone concentrations in postmortem cases, finding that poor and intermediate metabolizers have higher concentrations compared to extensive and ultra-rapid metabolizers. The distribution of CYP2D6 phenotypes was similar among different causes of death, indicating no overrepresentation of a particular phenotype in any cause of death group. Additionally, the ratio of oxymorphone to oxycodone is dependent on CYP2D6 activity, with a lower ratio indicating acute intake and potentially serving as a sensitive marker for distinguishing oxycodone intoxications from other causes of death.
FORENSIC SCIENCE INTERNATIONAL-GENETICS
(2021)
Review
Biochemistry & Molecular Biology
Lyubov S. Klyushova, Maria L. Perepechaeva, Alevtina Y. Grishanova
Summary: CYP3A enzymes metabolize various endogenous and exogenous compounds indiscriminately, with a unique ability to metabolize lipophilic substrates with large molecular weights. These enzymes are widely expressed in human tissues and play a crucial role in maintaining normal physiological levels and disease progression.
Article
Pharmacology & Pharmacy
Christian Skalafouris, Caroline Samer, Jerome Stirnemann, Olivier Grosgurin, Francois Eggimann, Damien Grauser, Jean-Luc Reny, Pascal Bonnabry, Bertrand Guignard
Summary: During Switzerland's first wave of COVID-19, clinical pharmacy activities were replaced by targeted remote interventions using the electronic PharmaCheck system. By screening high-risk situations of adverse drug events, particularly involving lopinavir/ritonavir and hydroxychloroquine prescriptions, the system triggered alerts and proposed therapeutic optimization, such as dose adjustments and additional monitoring, resulting in improved patient care.
EUROPEAN JOURNAL OF HOSPITAL PHARMACY
(2023)
Letter
Pharmacology & Pharmacy
Jean Terrier, Camille Lenoir, Caroline Samer
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Endocrinology & Metabolism
Giacomo Buso, Lucie Favre, Nathalie Vionnet, Elena Gonzalez-Rodriguez, Didier Hans, Jardena Jacqueline Puder, Celine Dubath, Chin-Bin Eap, Wassim Raffoul, Tinh-Hai Collet, Lucia Mazzolai
Summary: This study aimed to investigate regional body composition by DXA in patients with lipedema and healthy controls, and to determine cut-off values of FM indices for diagnosis and staging. The results showed significant differences in FM distribution indices between groups, with the leg FM/total FM ratio being a potentially useful indicator of lipedema.
Correction
Medicine, General & Internal
Jean Terrier, Frederic Gaspar, Pierre Fontana, Youssef Daali, Jean-Luc Reny, Chantal Csajka, Caroline F. Samer
AMERICAN JOURNAL OF MEDICINE
(2023)
Article
Pharmacology & Pharmacy
Christian Skalafouris, Anne-Laure Blanc, Olivier Grosgurin, Christophe Marti, Caroline Samer, Christian Lovis, Pascal Bonnabry, Bertrand Guignard
Summary: The study developed electronic queries to assist pharmacists in medication reviews and assessed their performance in detecting drug-related problems (DRPs). The results showed that these electronic queries had high sensitivity and negative predictive value, which can contribute to improving clinical decision support systems.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY
(2023)
Article
Ethics
Cristina Bosmani, Sonia Carboni, Caroline Samer, Christian Lovis, Thomas Perneger, Angela Huttner, Bernard Hirschel
Summary: In this study, consent bias was assessed in a cohort of over 40,000 adult patients asked to provide consent for the use of their clinical and biological data. The results showed that older patients with more comorbidities and Swiss nationality were more likely to provide consent, indicating a potential bias in actively seeking consent and compromising the external validity of data obtained.
BMC MEDICAL ETHICS
(2023)
Article
Pharmacology & Pharmacy
Frederique Rodieux, Youssef Daali, Victoria Rollason, Caroline F. Samer, Kuntheavy Ing Lorenzini
Summary: Pharmacokinetics in children is highly variable due to various factors including ontogeny, pharmacogenetics, gender, comorbidities, and drug-drug interactions. Understanding the impact of genetic polymorphisms on drug metabolism and response is lacking in pediatric population. This study aimed to investigate the use of cytochromes P450 (CYP) genotyping and phenotyping tests in children and assess the correlation between genotype and phenotype.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Pharmacology & Pharmacy
Ali El Rida El Masri, Caroline Tobler, Breunis Willemijn, Andre O. Von Bueren, Marc Ansari, Caroline Flora Samer
Summary: Methotrexate is an immunosuppressant and chemotherapeutic agent used for treating autoimmune disorders and cancers. Its main adverse effects are bone marrow suppression and gastrointestinal complications, but hepatotoxicity and nephrotoxicity are also common.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Genetics & Heredity
Aurelien Simona, Wenyu Song, David W. Bates, Caroline Flora Samer
Summary: Pharmacogenomics (PGx) aims to personalize drug therapy based on patient's genetic makeup. Polygenic risk scores (PRS) have emerged as a promising tool to consider the complex interplay and polygenic nature of patients' genetic predisposition affecting drug response. However, there is still a need to demonstrate the clinical utility and implementation of PRS in daily care, and collaboration between bioinformatician, treating physicians, and genetic consultants is crucial for transparent and trustworthy integration of PRS results into real-world medical decisions.
FRONTIERS IN GENETICS
(2023)
Article
Pharmacology & Pharmacy
Lea Darnaud, Clement Delage, Youssef Daali, Anne-Priscille Trouvin, Serge Perrot, Nihel Khoudour, Nadia Merise, Laurence Labat, Bruno Etain, Frank Bellivier, Celia Lloret-Linares, Vanessa Bloch, Emmanuel Curis, Xavier Decleves
Summary: Drug-metabolizing enzymes and drug transporters play crucial roles in drug pharmacokinetics and response. The cocktail-based phenotyping approach involves administering multiple probe drugs to evaluate the activities of CYP and transporter simultaneously. This study determined the range of phenotyping indices in healthy volunteers and classified patients with therapeutic issues based on CYP and P-gp activities.
Article
Health Care Sciences & Services
Hengameh Ghasim, Mohammadreza Rouini, Saeed Safari, Farnoosh Larti, Mohammadreza Khoshayand, Kheirollah Gholami, Navid Neyshaburinezhad, Yvonne Gloor, Youssef Daali, Yalda H. Ardakani
Summary: Comparing the effects of bariatric surgery on CYP-mediated drug elimination in comparable patients before and after surgery can reduce inter-individual variability of CYP450s enzyme activity. The current research evaluates the activities of six CYP isoforms and P-gp using a low-dose phenotyping cocktail. The results show increased enzyme activity after weight reduction following surgery, with statistical significance in CYP3A, CYP2B6, CYP2C9, and CYP1A2.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Chemistry, Medicinal
Frederique Rodieux, Flavia Storelli, Francois Curtin, Sergio Manzano, Alain Gervaix, Klara M. Posfay-Barbe, Jules Desmeules, Youssef Daali, Caroline F. Samer
Summary: The study aimed to evaluate pupillometry as a phenotyping method for assessing CYP2D6 activity in children treated with tramadol. The results showed that tramadol affected pupillary parameters in children, but a correlation between pupillometry measurements and CYP2D6 activity could not be identified.
Meeting Abstract
Pharmacology & Pharmacy
K. Abouir, P. Gosselin, S. Guerrier, Y. Daali, J. Desmeules, O. Grosgurin, J. Reny, C. Samer, A. Calmy, K. Lorenzini
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
(2022)
Meeting Abstract
Pharmacology & Pharmacy
A. Nikolaou, A. Craig, Ing K. Lorenzini, J. Desmeules, C. Samer, F. Rodieux
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
(2022)
Meeting Abstract
Pharmacology & Pharmacy
C. Lenoir, J. Terrier, Y. Gloor, Y. Daali, P. Gosselin, A. Niederer, Doffey F. Lazeyras, J. Desmeules, C. Samer, J. Reny, V Rollason
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
(2022)